Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Econazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 14/20 | 0.88 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.88 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.88 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.88 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.88 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.88 |
| ▸ | LMNA | P02545 | 4/20 | 0.88 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.88 |
| ▸ | PGR | P06401 | 4/20 | 0.88 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.88 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.88 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.88 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.88 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.88 |
| ▸ | MEN1 | O00255 | 3/20 | 0.88 |
| ▸ | TSHR | P16473 | 3/20 | 0.88 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.88 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.88 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.88 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Econazole SCHEMBL29440264 | 0.94 | IDO1 (1.00) | IDO1CYP2C9CYP3A4CYP1A2CYP2D6 | |
| Econazole SCHEMBL34498 | 0.94 | IDO1 (1.00) | IDO1CYP2C9CYP3A4CYP1A2CYP2D6 | |
| Econazole SCHEMBL20482166 | 0.94 | IDO1 (1.00) | IDO1CYP2C9CYP3A4CYP1A2CYP2D6 | |
| Econazole SCHEMBL7602990 | 0.94 | IDO1 (1.00) | IDO1CYP2C9CYP3A4CYP1A2CYP2D6 | |
| Econazole SCHEMBL34499 | 0.94 | IDO1 (1.00) | IDO1CYP2C9CYP3A4CYP1A2CYP2D6 | |
| Econazole SCHEMBL7602993 | 0.94 | IDO1 (1.00) | IDO1CYP2C9CYP3A4CYP1A2CYP2D6 | |
| Econazole SCHEMBL2483076 | 0.91 | IDO1 (0.95) | IDO1CYP2C9CYP3A4CYP1A2CYP2D6 | |
| Miconazole SCHEMBL1141531 | 0.90 | IDO1 (0.88) | IDO1CYP2C9CYP3A4CYP1A2CYP2D6 | |
| Isoconazole SCHEMBL9710582 | 0.89 | IDO1 (0.90) | IDO1CYP2C9CYP3A4CYP1A2CYP2D6 | |
| Miconazole SCHEMBL3226260 | 0.88 | IDO1 (0.89) | IDO1CYP2C9CYP3A4CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2467398-B1 | TRPC4 INHIBITORS AND USES THEREOF | POSEIDA THERAPEUTICS INC (US) | 2019-10-09 | — | — | EP | disclosed |
| US-20180030108-A1 | NOVEL VOLTAGE-DEPENDENT ION CHANNEL FUSIONS AND METHOD OF USE THEREOF | UNIV BORDEAUX (FR) | 2018-02-01 | — | — | US | disclosed |
| EP-3259595-A1 | NOVEL VOLTAGE-DEPENDENT ION CHANNEL FUSIONS AND METHOD OF USE THEREOF | Université de Bordeaux (FR) | 2017-12-27 | — | — | EP | disclosed |
| WO-2016131832-A1 | NOVEL VOLTAGE-DEPENDENT ION CHANNEL FUSIONS AND METHOD OF USE THEREOF | Universite de Bordeaux (FR) | 2016-08-25 | — | — | WO | disclosed |
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRANSPOSAGEN BIOPHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-5582832-A | CONTAINS AN AZOLE IN COMBINATION WITH A LIPID INGREDIENT; APPLYING TO IMPROVE OR PREVENT THE APPEARANCE OF WRINKLED, FLAKY, AGED OR PHOTODAMAGED SKIN | CHESEBROUGH-POND'S USA CO., DIVISION OF CONOPCO, INC. (US) | 1996-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120148604-A1 | TRP INHIBITORS AND USES THEREOF | TRPC4, TRPC1, TRPC3 | IDO1 829/4885CYP2C9 4869/4885CYP3A4 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.